

<b>Statement of Withdrawal of the Study</b>
<b>Sponsor :</b> Incyte Corporation
<b>Study # :</b> INCB 24360-310 (EudraCT#2017-003305-18)
<b>Product:</b> INCB 24360
<b>Study Title :</b> A Randomized, Global, Phase 3 Trial of Nivolumab Plus Epacadostat in Combination with Chemotherapy (platinum + 5-fluorouracil) versus the EXTREME Regimen (cetuximab + platinum + 5-fluorouracil) in First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
<b>Phase:</b> III
<b>Study Period:</b> NA
<b>Centres:</b> NA
<b>Number of Subjects:</b> 0
<b>Publications:</b> NA
<b>Statement on withdrawal of the study:</b> This study was prematurely ended prior to the start of enrollment by the Sponsor. Globally no subjects were enrolled into the study. Therefore no results / data are available.